ESP Block with Bupivacaine
ApprovedSmall molecule
ESP Block with Bupivacaine is one of 63 small molecule programs targeting Rib Fracture. It is currently in Approved.
3
Indications
2
Total Trials
1
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Spinal Fusion
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Marcaine
IInnocoll
Approved
Decadron
AAspen Global Incorporated
Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Toradol
JJavelin Pharmaceuticals
Approved
Forteo
AAlmaject
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ESP Block with Bupivacaine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- YYale University